TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00107757
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04158453
Drug: AUT00201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of AUT00201
Study: NCT04158453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of placebo
Study: NCT01745380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
Study: NCT01193283
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 my/kg for 4 days
Study: NCT00803335
Drug: Vaginal conjugated estrogen cream 0.5gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
Study: NCT00803335
Drug: Vaginal conjugated estrogen cream 1.0gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
Study: NCT01502202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
Study: NCT00549549
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indomethacin 50 mg three times a day (TID) for 8 days.
Study: NCT00549549
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
Study: NCT00549549
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
Study: NCT00549549
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 50 mg two times a day (BID) for 8 days
Study: NCT01509612
Drug: Additive classical homeopathy
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic remedies every 2 to 3 months
Study: NCT01509612
Drug: Homeopathic Placebo globules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic placebo globules every 2 to 3 months
Study: NCT04271514
Drug: RPT193
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonist of the CCR4 chemokine receptor
Study: NCT04271514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00649077
Drug: Meloxicam Tablets 15 mg
Normalized name: meloxicam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, single dose fasting
Study: NCT00649077
Drug: Mobic® Tablets 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, single dose fasting
Study: NCT02288819
Drug: Loop diuretic downtitration
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose \>40 mg furosemide OR \>1 mg bumetanide OR \>20 mg torsemide, the loop diuretic dose is halved.
Study: NCT02169843
Drug: Placebo(for Dexmedetomidine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
Study: NCT01918657
Drug: walnut powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
Study: NCT01918657
Drug: walnut powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalating doses of walnut powder
Study: NCT02510612
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
Study: NCT01372826
Drug: NKTR118 Group1
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, 25 mg
Study: NCT01372826
Drug: NKTR118 Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, 25 mg
Study: NCT01372826
Drug: NKTR118 Group3
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, 25 mg
Study: NCT01372826
Drug: NKTR118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, 25 mg
Study: NCT02266589
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Study: NCT02824627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive substance administered in volume equivalent to volume administered in active treatment arm.
Study: NCT04303195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT03202446
Drug: 1% Glycated Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03202446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03202446
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03202446
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02216279
Drug: PulmoBind
Approvals — FDA: no, EMA: no, PMDA: no
Description: PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
Study: NCT03099603
Drug: HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small molecular compound for the treatment of primary sclerosing cholangitis
Study: NCT01074177
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once a day
Study: NCT00870467
Drug: Double-blind Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
Study: NCT00691288
Drug: Omega Pure followed by placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
Study: NCT00691288
Drug: Placebo followed by Omega Pure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
Study: NCT01454011
Drug: Testosterone 50mg transdermal application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of testosterone 50mg transdermal gel in every night
Study: NCT00003925
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000256
Drug: 80% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01070433
Drug: MEBO Wound Ointment (MEBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application twice a day
Study: NCT01878318
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: stable dose
Study: NCT02426034
Drug: ApatinibTablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Tablets, recommended dose of 850mg
Study: NCT03009877
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
Study: NCT04350645
Drug: Normal Saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mls normal saline 0.9% over 2 minutes
Study: NCT00498953
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00470171
Drug: Ursodesoxycholic acid
Normalized name: Tauroursodesoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00418028
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01153607
Drug: BAY1006578
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
Study: NCT01153607
Drug: BAY1006578
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
Study: NCT01153607
Drug: BAY1006578
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
Study: NCT02711358
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
Study: NCT01545141
Drug: Chemokin Modulatory Regimen (5 MU/m2)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
Study: NCT01545141
Drug: Chemokin Modulatory Regimen (10 MU/m2)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
Study: NCT01545141
Drug: Chemokin Modulatory Regimen (20 MU/m2)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
Study: NCT04041921
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00540670
Drug: E5555 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5555 100 mg (tablet) taken orally, once a day.
Study: NCT00540670
Drug: E5555 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5555 200 mg (tablet) taken orally, once a day.
Study: NCT00540670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet) taken orally, once a day.
Study: NCT04369846
Drug: Placebo onitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onitment application
Study: NCT04019145
Drug: EverX Posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: fiber reinforced bulk fill resin composite
Study: NCT04019145
Drug: Resins, Composite
Approvals — FDA: no, EMA: no, PMDA: no
Description: incremental packing of Nanohybrid Resin composite
Study: NCT04378569
Drug: ARQ-252 cream 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-252 cream 0.3%
Study: NCT04378569
Drug: ARQ-252 cream 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-252 cream 0.1%
Study: NCT04378569
Drug: ARQ-252 Vehicle Cream
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-252 Vehicle Cream
Study: NCT01844817
Drug: OGX-427
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
Study: NCT01844817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
Study: NCT00001296
Drug: tumor necrosis factor
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02252302
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
Study: NCT03114085
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
Study: NCT02402465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated by placebo
Study: NCT03263715
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly administration of Placebo subcutaneous from Baseline to Week 16.
Study: NCT00991029
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 8 tablets followed by one tablet daily for 89 days
Study: NCT02720081
Drug: MK-1029 150 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tablet administered orally, once a day (QD), at bedtime
Study: NCT02720081
Drug: MK-1029 Matching-image Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-image placebo tablet administered orally, QD, at bedtime
Study: NCT02845375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Study: NCT03263715
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
Study: NCT03654729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution in 20 mL single dose glass vials
Study: NCT01655992
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2500mg／m2／day divided into twice two weeks on one week off
Study: NCT01655992
Drug: S1 generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg／m2 bid four weeks on two weeks off
Study: NCT04481594
Drug: HPN-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
Study: NCT04481594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
Study: NCT00052078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were treated with a placebo pill.
Study: NCT03845517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05560945
Drug: 1.5% Arginine Dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste
Study: NCT01058291
Drug: KW-6500 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve weeks subcutaneous injection for the OFF state
Study: NCT03103256
Drug: YHP1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily (QD), 8 weeks
Study: NCT03103256
Drug: YHR1703
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily (QD), 8 weeks
Study: NCT03103256
Drug: YHR1704
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily (QD), 8 weeks
Study: NCT01450514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
Study: NCT02915172
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
Study: NCT00640939
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Study: NCT00640939
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Study: NCT00256932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02748057
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01990573
Drug: 0.4mg/kg IV methadon HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II will receive 0.4mg/kg IV methadone HCl.
Study: NCT00115206
Drug: Neulasta® (pegfilgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03944863
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04445090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00905632
Drug: Placebo + SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tid +SOC
Study: NCT04232644
Drug: ADAIR 10mg IR capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: manipulated ADAIR IR 3x10 mg capsules
Study: NCT00161434
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo for 8 weeks
Study: NCT00741689
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
Study: NCT00758498
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets, once daily in the morning for 3 days
Study: NCT00308516
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15
Study: NCT01229215
Drug: FCFD4514S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating intravitreal injection
Study: NCT01229215
Drug: sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating sham injection
Study: NCT04306497
Drug: TCM prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
Study: NCT02982889
Drug: Diluent for LIQ865
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
Study: NCT01951105
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take one 250mg naproxen tablet three times a day for 12 weeks.
Study: NCT00005959
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005959
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03787602
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
Study: NCT02781818
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.1 mL will be administered intralesionally at the selected site.
Study: NCT03166501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 60 min parenteral infusions over a 5 day period
Study: NCT01569945
Drug: Clomifen, Ethinyl Estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
Study: NCT00005916
Drug: rV-PSA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005916
Drug: rF-PSA
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005916
Drug: rV-B7.1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01957579
Drug: MEDI-551
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
Study: NCT02726789
Drug: REP 2139-Ca
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex